ERBB2 and cancer: Although a normal self-protein, it is often overexpressed in breast and ovarian cancers and can thus be selectively targeted by antibody; there are also a number of anti-Her2 therapies in early phases of clinical trials that seek to elicit T cell responses in cancer patients [10].